Reduced hospitalization for heart failure using anti-diabetic drug dapagliflozin: implications of DECLARE-TIMI 58 for the basic science community. [electronic resource]
Producer: 20200518Description: e54-e57 p. digitalISSN:- 1755-3245
- Benzhydryl Compounds -- adverse effects
- Biomarkers -- blood
- Blood Glucose -- drug effects
- Clinical Trials as Topic
- Diabetes Mellitus, Type 2 -- blood
- Glucosides -- adverse effects
- Heart Failure -- diagnosis
- Hospitalization
- Humans
- Risk Assessment
- Risk Factors
- Sodium-Glucose Transporter 2 Inhibitors -- adverse effects
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.